Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lessened its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 144,199 shares of the biotechnology company’s stock after selling 9,845 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Ascendis Pharma A/S were worth $19,852,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ASND. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $30,000. Jones Financial Companies Lllp raised its stake in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. lifted its holdings in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 328 shares in the last quarter. GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at $203,000.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $155.86 on Tuesday. The firm has a fifty day moving average price of $144.72 and a two-hundred day moving average price of $137.63. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37. The company has a market cap of $9.46 billion, a PE ratio of -21.95 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on ASND shares. Cantor Fitzgerald boosted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Evercore ISI boosted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.